000 01184 a2200313 4500
005 20250516050853.0
264 0 _c20111223
008 201112s 0 0 eng d
022 _a1365-2036
024 7 _a10.1111/j.1365-2036.2011.04778.x
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aDeshpande, A R
245 0 0 _aPrediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
_h[electronic resource]
260 _bAlimentary pharmacology & therapeutics
_cSep 2011
300 _a586 p.
_bdigital
500 _aPublication Type: Letter; Comment
650 0 4 _aAntibodies, Monoclonal
_xtherapeutic use
650 0 4 _aCrohn Disease
_xdiagnosis
650 0 4 _aFeces
_xchemistry
650 0 4 _aFemale
650 0 4 _aGastrointestinal Agents
_xtherapeutic use
650 0 4 _aHumans
650 0 4 _aLeukocyte L1 Antigen Complex
_xmetabolism
650 0 4 _aMale
650 0 4 _aTumor Necrosis Factor-alpha
_xtherapeutic use
700 1 _aStrobel, S
773 0 _tAlimentary pharmacology & therapeutics
_gvol. 34
_gno. 5
_gp. 586
856 4 0 _uhttps://doi.org/10.1111/j.1365-2036.2011.04778.x
_zAvailable from publisher's website
999 _c21052299
_d21052299